Schedule 13D ownership disclosure

AN2 Therapeutics, Inc.

Common Stock, par value $0.00001 per share · CUSIP: 037326105

Event date: 2025-05-07

Filing-level shares
5,749,432
Percent of class
19.1%
  • BML Investment Partners, L.P.Reported CIK 0001373604

    Shares: 5,749,432 · Class: 19.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001373604-25-000074
Form type
SCHEDULE 13D
Filer
AN2 Therapeutics, Inc.
CIK
CIK 1880438
Filed
May 07, 2025
Reporting period
May 07, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub